{"id":29696,"date":"2025-02-27T09:28:56","date_gmt":"2025-02-27T08:28:56","guid":{"rendered":"https:\/\/mabdesign.fr\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/"},"modified":"2025-02-27T09:33:06","modified_gmt":"2025-02-27T08:33:06","slug":"mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/","title":{"rendered":"Mabqi, the French specialist in therapeutic antibodies for oncology, obtains \u20ac5 million in non-dilutive financing from France 2030&#8217;s \u201cInnovations in Biotherapies and Bioproduction\u201d call for projects"},"content":{"rendered":"\n<p>Grabels, France, February 26, 2025 &#8211; Mabqi, a biotechnology company specializing in the development of therapeutic antibodies for the treatment of cancer, today announced that it has obtained \u20ac5 million in funding from the French government under the Innovations in Biotherapies and Bioproduction call for projects under of the France 2030 program operated on behalf of the French government by Bpifrance.<br>Mabqi develops a first-in-class MQI-201 antibody that specifically targets TRPV6 ion channel, an innovative therapeutic target in oncology involved in the development of several cancers with high medical need, including prostate cancer. This funding will enable Mabqi to launch the bioproduction of this antibody, to carry out all the regulatory preclinical stages and to conduct an initial Phase 1a clinical study, which is scheduled to start early 2027. <a href=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/02\/PR_Mabqi_BPI_02262025_EN_vF.pdf\">To know more<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mabqi, a biotechnology company specializing in the development of therapeutic antibodies for the treatment of cancer, today announced that it has obtained \u20ac5 million in funding from the French government under the Innovations in Biotherapies and Bioproduction call for projects under of the France 2030 program operated on behalf of the French government by Bpifrance.<\/p>\n","protected":false},"author":3,"featured_media":7366,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9,36,13,32],"tags":[],"class_list":["post-29696","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites","category-news","category-nos-adherents","category-our-members"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Mabqi, the French specialist in therapeutic antibodies for oncology, obtains \u20ac5 million in non-dilutive financing from France 2030&#039;s \u201cInnovations in Biotherapies and Bioproduction\u201d call for projects - MabDesign<\/title>\n<meta name=\"description\" content=\"Mabqi, a biotechnology company specializing in the development of therapeutic antibodies for the treatment of cancer, today announced that it has obtained \u20ac5 million in funding from the French government under the Innovations in Biotherapies and Bioproduction call for projects under of the France 2030 program operated on behalf of the French government by Bpifrance. Mabqi, a biotechnology company specializing in the development of therapeutic antibodies for the treatment of cancer, today announced that it has obtained \u20ac5 million in funding from the French government under the Innovations in Biotherapies and Bioproduction call for projects under of the France 2030 program operated on behalf of the French government by Bpifrance.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mabqi, the French specialist in therapeutic antibodies for oncology, obtains \u20ac5 million in non-dilutive financing from France 2030&#039;s \u201cInnovations in Biotherapies and Bioproduction\u201d call for projects - MabDesign\" \/>\n<meta property=\"og:description\" content=\"Mabqi, a biotechnology company specializing in the development of therapeutic antibodies for the treatment of cancer, today announced that it has obtained \u20ac5 million in funding from the French government under the Innovations in Biotherapies and Bioproduction call for projects under of the France 2030 program operated on behalf of the French government by Bpifrance. Mabqi, a biotechnology company specializing in the development of therapeutic antibodies for the treatment of cancer, today announced that it has obtained \u20ac5 million in funding from the French government under the Innovations in Biotherapies and Bioproduction call for projects under of the France 2030 program operated on behalf of the French government by Bpifrance.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-27T08:28:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-27T08:33:06+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/Mabqi.png\" \/>\n\t<meta property=\"og:image:width\" content=\"250\" \/>\n\t<meta property=\"og:image:height\" content=\"94\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Laure Delhon\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Laure Delhon\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/\"},\"author\":{\"name\":\"Laure Delhon\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39\"},\"headline\":\"Mabqi, the French specialist in therapeutic antibodies for oncology, obtains \u20ac5 million in non-dilutive financing from France 2030&#8217;s \u201cInnovations in Biotherapies and Bioproduction\u201d call for projects\",\"datePublished\":\"2025-02-27T08:28:56+00:00\",\"dateModified\":\"2025-02-27T08:33:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/\"},\"wordCount\":152,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/Mabqi.png\",\"articleSection\":[\"Actualit\u00e9s\",\"News\",\"Nos adh\u00e9rents\",\"Our members\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/\",\"name\":\"Mabqi, the French specialist in therapeutic antibodies for oncology, obtains \u20ac5 million in non-dilutive financing from France 2030's \u201cInnovations in Biotherapies and Bioproduction\u201d call for projects - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/Mabqi.png\",\"datePublished\":\"2025-02-27T08:28:56+00:00\",\"dateModified\":\"2025-02-27T08:33:06+00:00\",\"description\":\"Mabqi, a biotechnology company specializing in the development of therapeutic antibodies for the treatment of cancer, today announced that it has obtained \u20ac5 million in funding from the French government under the Innovations in Biotherapies and Bioproduction call for projects under of the France 2030 program operated on behalf of the French government by Bpifrance. Mabqi, a biotechnology company specializing in the development of therapeutic antibodies for the treatment of cancer, today announced that it has obtained \u20ac5 million in funding from the French government under the Innovations in Biotherapies and Bioproduction call for projects under of the France 2030 program operated on behalf of the French government by Bpifrance.\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/#primaryimage\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/Mabqi.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/Mabqi.png\",\"width\":250,\"height\":94},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mabqi, the French specialist in therapeutic antibodies for oncology, obtains \u20ac5 million in non-dilutive financing from France 2030&rsquo;s \u201cInnovations in Biotherapies and Bioproduction\u201d call for projects\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39\",\"name\":\"Laure Delhon\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g\",\"caption\":\"Laure Delhon\"},\"url\":\"https:\/\/mabdesign.fr\/en\/author\/laure-delhonmabdesign-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mabqi, the French specialist in therapeutic antibodies for oncology, obtains \u20ac5 million in non-dilutive financing from France 2030's \u201cInnovations in Biotherapies and Bioproduction\u201d call for projects - MabDesign","description":"Mabqi, a biotechnology company specializing in the development of therapeutic antibodies for the treatment of cancer, today announced that it has obtained \u20ac5 million in funding from the French government under the Innovations in Biotherapies and Bioproduction call for projects under of the France 2030 program operated on behalf of the French government by Bpifrance. Mabqi, a biotechnology company specializing in the development of therapeutic antibodies for the treatment of cancer, today announced that it has obtained \u20ac5 million in funding from the French government under the Innovations in Biotherapies and Bioproduction call for projects under of the France 2030 program operated on behalf of the French government by Bpifrance.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/","og_locale":"en_US","og_type":"article","og_title":"Mabqi, the French specialist in therapeutic antibodies for oncology, obtains \u20ac5 million in non-dilutive financing from France 2030's \u201cInnovations in Biotherapies and Bioproduction\u201d call for projects - MabDesign","og_description":"Mabqi, a biotechnology company specializing in the development of therapeutic antibodies for the treatment of cancer, today announced that it has obtained \u20ac5 million in funding from the French government under the Innovations in Biotherapies and Bioproduction call for projects under of the France 2030 program operated on behalf of the French government by Bpifrance. Mabqi, a biotechnology company specializing in the development of therapeutic antibodies for the treatment of cancer, today announced that it has obtained \u20ac5 million in funding from the French government under the Innovations in Biotherapies and Bioproduction call for projects under of the France 2030 program operated on behalf of the French government by Bpifrance.","og_url":"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/","og_site_name":"MabDesign","article_published_time":"2025-02-27T08:28:56+00:00","article_modified_time":"2025-02-27T08:33:06+00:00","og_image":[{"width":250,"height":94,"url":"http:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/Mabqi.png","type":"image\/png"}],"author":"Laure Delhon","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"Laure Delhon","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/"},"author":{"name":"Laure Delhon","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39"},"headline":"Mabqi, the French specialist in therapeutic antibodies for oncology, obtains \u20ac5 million in non-dilutive financing from France 2030&#8217;s \u201cInnovations in Biotherapies and Bioproduction\u201d call for projects","datePublished":"2025-02-27T08:28:56+00:00","dateModified":"2025-02-27T08:33:06+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/"},"wordCount":152,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/Mabqi.png","articleSection":["Actualit\u00e9s","News","Nos adh\u00e9rents","Our members"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/","url":"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/","name":"Mabqi, the French specialist in therapeutic antibodies for oncology, obtains \u20ac5 million in non-dilutive financing from France 2030's \u201cInnovations in Biotherapies and Bioproduction\u201d call for projects - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/#primaryimage"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/Mabqi.png","datePublished":"2025-02-27T08:28:56+00:00","dateModified":"2025-02-27T08:33:06+00:00","description":"Mabqi, a biotechnology company specializing in the development of therapeutic antibodies for the treatment of cancer, today announced that it has obtained \u20ac5 million in funding from the French government under the Innovations in Biotherapies and Bioproduction call for projects under of the France 2030 program operated on behalf of the French government by Bpifrance. Mabqi, a biotechnology company specializing in the development of therapeutic antibodies for the treatment of cancer, today announced that it has obtained \u20ac5 million in funding from the French government under the Innovations in Biotherapies and Bioproduction call for projects under of the France 2030 program operated on behalf of the French government by Bpifrance.","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/#primaryimage","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/Mabqi.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/Mabqi.png","width":250,"height":94},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/mabqi-specialiste-francais-des-anticorps-therapeutiques-en-oncologie-obtient-un-financement-de-5-me-dans-le-cadre-de-lappel-a-projets-innovations-en-biotherapies-et-bioproduction\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Mabqi, the French specialist in therapeutic antibodies for oncology, obtains \u20ac5 million in non-dilutive financing from France 2030&rsquo;s \u201cInnovations in Biotherapies and Bioproduction\u201d call for projects"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39","name":"Laure Delhon","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g","caption":"Laure Delhon"},"url":"https:\/\/mabdesign.fr\/en\/author\/laure-delhonmabdesign-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/29696","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=29696"}],"version-history":[{"count":1,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/29696\/revisions"}],"predecessor-version":[{"id":29698,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/29696\/revisions\/29698"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media\/7366"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=29696"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=29696"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=29696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}